Exosomes for Skin & Aesthetics: The Complete Guide

Overview

Exosomes are nanoscale extracellular vesicles — typically 30 to 150 nanometers in diameter — secreted by virtually all cell types. They function as intercellular messengers, carrying a cargo of proteins, lipids, messenger RNA (mRNA), and microRNA (miRNA) from one cell to another. When released by stem cells, exosomes deliver growth factors and signaling molecules that can influence the behavior of recipient cells, including fibroblasts, keratinocytes, and endothelial cells in the skin (Hu et al., 2019).

In the aesthetic and dermatologic context, exosomes have emerged as a cell-free alternative to stem cell therapies. Rather than transplanting live stem cells — which carry risks of uncontrolled proliferation and immune rejection — exosome-based treatments deliver the paracrine signals (growth factors, cytokines, regulatory RNAs) that stem cells naturally produce. The hypothesis is that these signals can stimulate the skin's own cells to increase collagen and elastin production, accelerate wound healing, and reduce visible signs of aging (Cho et al., 2018).

Exosome-based skin treatments have gained significant traction in aesthetic medicine clinics, where they are marketed under names such as "exosome facial," "exosome skin rejuvenation," and "exosome therapy." These treatments typically involve applying exosome preparations topically — often in combination with microneedling, fractional laser, or radiofrequency devices — to enhance penetration through the skin barrier.

Despite their growing popularity, exosome-based aesthetic treatments are not FDA-approved. No exosome product has completed the regulatory pathway required for cosmetic or dermatologic approval. The FDA has issued public warnings to clinics marketing unapproved exosome products, citing concerns about product safety, contamination risk, and unverified efficacy claims. There is no standardization of exosome products — sourcing, concentration, cargo composition, and quality control vary widely between manufacturers and clinics.

Quick Facts

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

How It Works

The mechanism of exosome-mediated skin rejuvenation involves several interconnected biological processes. Unlike topical skincare ingredients that act on the skin surface, exosomes are internalized by recipient cells and deliver their cargo directly into the cell's interior — allowing them to influence gene expression and protein production at the cellular level.

Growth Factor Delivery

Exosomes derived from mesenchymal stem cells carry a concentrated payload of growth factors relevant to skin health:

• EGF (Epidermal Growth Factor) — stimulates keratinocyte proliferation and epidermal renewal, promoting faster skin turnover and improved texture (Cho et al., 2018)
• FGF (Fibroblast Growth Factor) — activates fibroblasts to produce collagen and elastin, the structural proteins responsible for skin firmness and elasticity
• VEGF (Vascular Endothelial Growth Factor) — promotes angiogenesis (new blood vessel formation) in the dermis, improving nutrient delivery and skin vitality
• PDGF (Platelet-Derived Growth Factor) — recruits and activates fibroblasts and other repair cells, accelerating tissue remodeling
• TGF-β (Transforming Growth Factor-beta) — regulates extracellular matrix production, including collagen deposition and wound contraction (Hu et al., 2019)

MicroRNA (miRNA) Signaling

Perhaps the most distinctive feature of exosome therapy compared to growth factor serums is the delivery of microRNAs — small non-coding RNA molecules that regulate gene expression in recipient cells. Key miRNAs identified in MSC-derived exosomes include:

• miR-21 — promotes fibroblast migration, collagen synthesis, and wound closure; inhibits apoptosis (programmed cell death) in skin cells (Hu et al., 2019)
• miR-29 — regulates collagen gene expression and extracellular matrix remodeling; involved in preventing excessive scarring
• miR-let-7 — modulates inflammatory pathways and cellular senescence; may contribute to anti-aging effects
• miR-125b — regulates keratinocyte differentiation and epidermal homeostasis

These miRNAs can silence or activate specific genes in skin cells, providing a level of biological regulation that topical growth factors alone cannot achieve. This gene-regulatory capacity is what distinguishes exosome therapy from conventional growth factor treatments in the literature.

Collagen and Elastin Synthesis

The primary aesthetic benefit attributed to exosomes is the stimulation of collagen and elastin production in dermal fibroblasts. In vitro studies have demonstrated that MSC-derived exosomes increase type I and type III collagen expression in human dermal fibroblasts in a dose-dependent manner (Cho et al., 2018). Elastin production — critical for skin elasticity and resilience — is similarly upregulated. This neocollagenesis (new collagen formation) is the biological basis for reported improvements in skin firmness, fine line reduction, and overall skin quality.

Wound Healing and Tissue Repair

Exosomes accelerate all phases of wound healing:

• Inflammatory phase: Exosomes modulate the inflammatory response, promoting a shift from pro-inflammatory (M1) to anti-inflammatory (M2) macrophage polarization, reducing excessive inflammation while maintaining necessary immune function (Hu et al., 2019)
• Proliferative phase: Exosomes stimulate fibroblast proliferation, keratinocyte migration, and angiogenesis — all critical for building new tissue at the wound site
• Remodeling phase: Exosome-delivered miRNAs help regulate extracellular matrix organization, potentially reducing scar formation and promoting more cosmetically favorable healing

Enhanced Penetration via Delivery Methods

The skin's stratum corneum (outermost barrier layer) prevents most topically applied molecules — including exosomes — from reaching the dermis where fibroblasts reside. This is why exosome treatments are typically combined with barrier-disrupting procedures:

• Microneedling: Creates thousands of microchannels in the skin (0.5–2.0 mm depth), allowing exosomes to penetrate directly into the dermis
• Fractional laser: Creates microscopic columns of thermal injury, providing both channels for exosome penetration and a wound-healing stimulus that synergizes with exosome signaling
• Radiofrequency: Creates thermal microinjury zones that enhance absorption and stimulate additional collagen remodeling

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Research

Skin Rejuvenation and Anti-Aging

• Cho et al. (2018): Investigated the effects of adipose-derived stem cell (ADSC) exosomes on human dermal fibroblasts. The study demonstrated that ADSC exosomes increased type I collagen and elastin gene expression in a dose-dependent manner. Exosome-treated fibroblasts showed enhanced proliferation and migration compared to controls. The researchers identified EGF, FGF, and PDGF as key cargo components mediating these effects (Cho et al., 2018).
• Exosome-enhanced microneedling studies: Several small clinical studies have examined the combination of exosomes with microneedling for facial rejuvenation. These studies report improvements in skin texture, fine lines, pore size, and overall skin quality scores compared to microneedling alone. However, most of these studies are limited by small sample sizes, lack of blinding, and short follow-up periods (Cho et al., 2018).
• Photoaging models: In UV-damaged skin models, MSC-derived exosomes reduced markers of photoaging (MMP-1 expression, collagen degradation) and increased procollagen synthesis, suggesting a mechanism for reversing UV-induced skin damage at the cellular level.

Wound Healing

• Hu et al. (2019): A comprehensive study examining MSC-derived exosomes in cutaneous wound healing. The researchers demonstrated that exosomes accelerated wound closure in a mouse full-thickness skin defect model, with enhanced re-epithelialization, collagen deposition, and angiogenesis at wound sites. The study identified miR-21 as a key mediator, promoting fibroblast function via the PI3K/Akt pathway. Exosome-treated wounds showed reduced scar width and improved cosmetic appearance compared to controls (Hu et al., 2019).
• Burn wound models: MSC-derived exosomes have shown benefit in animal burn models, with accelerated re-epithelialization, reduced inflammation, and improved tissue remodeling. These findings are relevant to post-procedure recovery applications in aesthetic medicine.
• Diabetic wound healing: Exosomes from various MSC sources have demonstrated accelerated healing of diabetic wounds in animal models — a particularly challenging clinical scenario due to impaired vascularity and immune function in diabetic tissue.

Skin Barrier Function

• Keratinocyte studies: In vitro research has shown that MSC-derived exosomes promote keratinocyte proliferation and migration, enhance tight junction protein expression, and improve skin barrier integrity. These findings have implications for post-procedure recovery and treatment of barrier-compromised skin conditions.

Pigmentation and Skin Tone

• Melanocyte regulation: Preliminary research suggests that certain exosome preparations may modulate melanocyte activity, with potential applications for hyperpigmentation. However, this area of research is early-stage, and clinical applications for pigmentation disorders remain unvalidated.

Post-Procedure Recovery

• Post-laser healing: Small clinical series have documented faster recovery and reduced downtime when exosomes are applied following ablative and non-ablative laser treatments. Reported benefits include reduced erythema (redness), faster re-epithelialization, and improved cosmetic outcomes. These reports lack controlled comparison groups in most cases.

Limitations of the Research

• Predominantly preclinical: The majority of evidence comes from in vitro (cell culture) and in vivo (animal) studies. Translation to human skin — with its distinct thickness, immune environment, and aging biology — is not guaranteed.
• No standardization: Different studies use exosomes from different cell sources (adipose MSCs, bone marrow MSCs, umbilical cord MSCs), different isolation methods, different concentrations, and different delivery protocols. This makes cross-study comparison difficult.
• Small human studies: The clinical studies that do exist are small (typically 10–30 subjects), often uncontrolled, and of short duration.
• Conflict of interest: Some published research is funded by or affiliated with companies that manufacture or market exosome products, introducing potential bias.
• No Phase 3 trials: No large randomized controlled trials have been completed for any aesthetic exosome indication.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Uses

FDA Status

No exosome product is FDA-approved for cosmetic, dermatologic, or aesthetic use. The FDA classifies exosome-based treatments as biological products that require approval through the Biologics License Application (BLA) pathway. No manufacturer has completed this process for an aesthetic exosome product. Clinics offering exosome treatments do so outside the FDA-approved framework.

Common Aesthetic Applications

Treatment Combinations

Exosome treatments are rarely performed as standalone procedures in clinical practice. Common combinations include:

• Microneedling + exosomes: The most common protocol. Microneedling creates dermal channels; exosomes are applied topically immediately after to penetrate the disrupted skin barrier.
• Fractional laser + exosomes: Exosomes applied after laser treatment to accelerate recovery and enhance collagen remodeling initiated by the laser.
• PRP + exosomes: Some clinics combine platelet-rich plasma with exosome preparations, though evidence for additive benefit is limited.
• Radiofrequency microneedling + exosomes: RF microneedling provides thermal injury at controlled depths; exosomes applied post-procedure.

What Exosomes Are NOT Used For

• Replacement for surgical procedures: Exosomes do not provide the structural changes achieved by facelift, blepharoplasty, or other surgical interventions.
• Deep wrinkle elimination: Exosomes may improve fine lines and skin quality but are not a substitute for neurotoxins (Botox) or dermal fillers for moderate-to-deep wrinkles and volume loss.
• Skin cancer treatment: Exosomes have no established role in dermatologic oncology.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Protocols

Commonly Reported Treatment Protocols

Typical Treatment Session

A standard exosome facial session generally follows this sequence:

1. Consultation and skin assessment — provider evaluates skin condition, concerns, and candidacy
2. Cleansing and preparation — skin thoroughly cleansed; topical numbing cream applied (20–30 minutes) if microneedling is performed
3. Procedure — microneedling, laser, or radiofrequency treatment performed according to provider protocol
4. Exosome application — exosome preparation applied topically to treated skin, massaged or pressed into microchannels
5. Post-treatment care — soothing mask or hydrating barrier applied; post-care instructions provided

Administration Considerations

• Concentration varies: Different exosome products contain widely varying concentrations of exosomes (often measured in particles per mL). There is no established minimum effective concentration for aesthetic applications.
• Source matters: Exosome cargo composition differs based on the parent cell type (adipose MSCs vs. bone marrow MSCs vs. umbilical cord MSCs). No consensus exists on which source is optimal for aesthetic applications.
• Storage: Most exosome preparations require refrigeration or frozen storage. Lyophilized (freeze-dried) formulations are more shelf-stable. Reconstitution protocols vary by manufacturer.
• Volume: Typical topical application volumes range from 1–5 mL per treatment session, depending on the treatment area and product concentration.

Post-Treatment Care

• Avoid direct sun exposure for 48–72 hours post-treatment
• Do not wash the treated area for 4–6 hours to allow exosome absorption
• Avoid active skincare ingredients (retinoids, AHAs, vitamin C) for 24–48 hours
• Use gentle, hydrating skincare products for the first 3–5 days
• Apply broad-spectrum SPF 30+ sunscreen daily

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Results: What Users Report

Reported Timeline

Commonly Reported Improvements

• Improved skin texture and smoothness
• Enhanced skin hydration and "glow"
• Reduction in fine lines (particularly periorbital and perioral)
• Smaller-appearing pores
• More even skin tone and reduced mild hyperpigmentation
• Improved skin firmness and elasticity
• Faster recovery from laser and microneedling procedures
• Improvement in acne scar appearance (over multiple sessions)

What "Results" Means Without Controlled Data

• Procedure contribution: Microneedling and laser treatments themselves stimulate collagen production independently of exosomes. It is difficult to determine how much of the observed benefit comes from the exosomes versus the delivery procedure.
• Placebo effect: Aesthetic treatments carry a substantial placebo component — the expectation of improvement, the ritual of treatment, and the investment of time and money all contribute to perceived benefit.
• Selection bias: Clinics and satisfied patients are more likely to share positive outcomes than negative ones.
• No dose-response established: Without controlled studies comparing different exosome concentrations to placebo, the optimal "dose" and true magnitude of benefit are unknown.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Side Effects

Reported Side Effects

Theoretical and Emerging Concerns

• Product contamination: The FDA has raised concerns about exosome products manufactured without adequate quality controls. Unregulated products may contain infectious agents, endotoxins, or other contaminants. In 2019, the FDA issued a safety alert after patients were hospitalized following injections of unapproved exosome products (FDA Safety Communication).
• Batch variability: Without standardized manufacturing processes, the composition and potency of exosome products can vary between batches and between manufacturers. Patients may receive inconsistent products across treatment sessions.
• Unknown long-term effects: The long-term effects of repeated exosome application to skin tissue are not established. While no long-term adverse effects have been reported, the treatment is relatively new and follow-up data is limited.
• Theoretical tumor promotion: Exosomes carry pro-angiogenic growth factors (VEGF) that could theoretically promote blood vessel formation around pre-existing tumors. This concern is theoretical and has not been documented in clinical use for aesthetic applications, but individuals with active skin malignancies should avoid exosome treatments.
• Immune sensitization: Repeated exposure to exosomes from allogeneic (donor) sources could theoretically trigger immune sensitization, though this has not been clinically documented with topical application.

Contraindications

• Active skin infection (bacterial, viral, or fungal) in the treatment area
• Active skin cancer or history of skin cancer in the treatment area
• Active acne vulgaris (moderate to severe) — treatment may exacerbate breakouts
• Pregnancy and breastfeeding — no safety data available
• Active herpes simplex — microneedling can trigger HSV reactivation; antiviral prophylaxis may be required
• Keloid or hypertrophic scarring tendency — microneedling component may stimulate excessive scarring
• Immunosuppression — impaired wound healing and increased infection risk
• Blood-thinning medications — increased bruising risk with microneedling (relative contraindication)

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Regulatory Status

FDA Position

The FDA classifies exosome products as biological products regulated under Section 351 of the Public Health Service Act. This means:

• Exosome products intended for therapeutic or aesthetic use require a Biologics License Application (BLA) — the same approval pathway required for vaccines, blood products, and cell therapies
• No exosome product has received a BLA for any aesthetic indication
• Marketing exosome products for therapeutic or cosmetic purposes without FDA approval violates federal law
• The FDA has exercised enforcement discretion in some cases but has issued formal warnings and taken action against specific clinics and manufacturers

FDA Enforcement Actions

How Clinics Operate

Despite the regulatory landscape, exosome aesthetic treatments are widely offered in the United States and internationally. Clinics typically operate under one or more of the following frameworks:

• Practice of medicine: Some clinics argue that exosome application falls under the physician's practice of medicine, which is regulated at the state level rather than by the FDA.
• "Cosmetic" positioning: Some products are marketed as cosmetic topical preparations rather than biological therapeutics, though the FDA has not endorsed this distinction for exosome products.
• Research use: Some exosome products are sold labeled "for research use only" — similar to the peptide market.
• Regulatory gray area: The enforcement landscape is evolving, and many clinics operate in areas where FDA enforcement has not yet reached.

No Product Standardization

A critical regulatory concern is the complete absence of standardization across exosome products used in aesthetic medicine:

• No USP monograph or pharmacopeial standard exists for exosome preparations
• Exosome concentration, cargo composition, and purity vary between manufacturers
• Isolation methods differ (ultracentrifugation, size exclusion, tangential flow filtration) and produce products with different characteristics
• Quality control testing is not standardized — some manufacturers test for particle count and size distribution; others provide minimal characterization
• The term "exosome" is used loosely in the aesthetic market — some products may contain mixed extracellular vesicle populations or conditioned media rather than purified exosomes

International Regulatory Landscape

Exosome products face similar regulatory challenges internationally. Most major regulatory agencies (EMA, MHRA, TGA, Health Canada) classify exosome therapies as advanced therapy medicinal products (ATMPs) or biological products requiring formal approval. Some countries with less restrictive regulatory frameworks permit exosome treatments under different oversight models.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Cost

Typical Pricing

Insurance Coverage

No insurance plan covers exosome aesthetic treatments. Because no exosome product has FDA approval for any cosmetic or dermatologic indication, these treatments cannot be billed to medical insurance, HSA/FSA accounts (in most cases), or any health benefit plan. All costs are out-of-pocket.

Factors Affecting Cost

• Geographic market: Treatments in major metropolitan areas (New York, Los Angeles, Miami) tend to cost more than in smaller markets.
• Clinic positioning: Medical spas and boutique aesthetic clinics may charge premium prices compared to dermatology practices.
• Exosome product: Different exosome products carry different wholesale costs. Products with more rigorous quality testing and characterization tend to be more expensive.
• Delivery method: Laser-based delivery is typically more expensive than microneedling-based delivery due to higher equipment and treatment costs.
• Provider expertise: Board-certified dermatologists and plastic surgeons may charge more than nurse practitioners or aestheticians.
• Treatment area: Full-face treatments cost more than targeted areas (under-eye, neck only).

Cost Comparison: Exosomes vs. Related Treatments

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Questions & Answers

Myth: "Exosome facials are FDA-approved."

Fact: No exosome product is FDA-approved for any cosmetic, aesthetic, or dermatologic indication. The FDA has explicitly warned consumers and clinics about unapproved exosome products (FDA Safety Communication). Clinics offering exosome treatments do so outside the FDA approval framework. The term "FDA-cleared" is sometimes used misleadingly — FDA clearance of a microneedling device does not extend to the exosome product applied during the procedure.

Myth: "Exosomes are the same as stem cells."

Fact: Exosomes are not cells. They are nano-sized vesicles secreted by cells — including stem cells. Exosome therapy is a cell-free approach: no live cells are transplanted. This distinction matters because exosomes do not carry the same risks as live stem cell transplantation (uncontrolled cell proliferation, tumor formation, immune rejection). However, they also may not provide the full range of effects that live stem cells could theoretically deliver, since they carry only a subset of the stem cell's signaling molecules.

Myth: "All exosome products are the same."

Fact: Exosome products vary enormously in source, isolation method, concentration, cargo composition, and quality. Exosomes from adipose-derived MSCs carry different growth factors and miRNAs than those from bone marrow MSCs or umbilical cord MSCs. Isolation method (ultracentrifugation vs. size exclusion chromatography vs. tangential flow filtration) affects purity and yield. Some products marketed as "exosomes" may contain mixed extracellular vesicle populations, conditioned media, or exosome-depleted preparations. Without standardization, product quality is highly variable.

Myth: "Exosome treatments replace Botox and fillers."

Fact: Exosomes and injectable aesthetics (neurotoxins, dermal fillers) address different aspects of facial aging. Exosomes target skin quality at the cellular level — collagen production, texture, tone. Botox addresses dynamic wrinkles by relaxing facial muscles. Fillers restore volume loss. These are complementary, not interchangeable approaches. An exosome facial does not relax forehead lines or restore cheek volume the way Botox and fillers do.

Myth: "Exosome facials are completely risk-free."

Fact: While the delivery procedures (microneedling, laser) are well-established with known safety profiles, the exosome component introduces uncertainties. The 2019 FDA safety alert documented serious infections from contaminated exosome products. Without standardized manufacturing, the risk of contamination, inconsistent potency, or unwanted biological activity cannot be fully excluded. Additionally, the long-term effects of repeated exosome application to skin are not established.

Myth: "You can get the same results with exosome skincare products."

Fact: Over-the-counter skincare products marketed as containing "exosomes" are a growing market segment. However, intact exosomes cannot penetrate the skin barrier (stratum corneum) when applied topically without barrier disruption. Products applied to intact skin — without microneedling or laser — are unlikely to deliver exosomes to dermal fibroblasts. Additionally, the stability of exosomes in commercial skincare formulations is uncertain, and many consumer products may contain exosome fragments, conditioned media, or exosome-derived proteins rather than intact, functional exosomes.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Key Takeaways

Based on the available evidence:

• Exosomes are nanoscale extracellular vesicles that carry growth factors (EGF, FGF, VEGF, PDGF), cytokines, and regulatory miRNAs from stem cells to target skin cells. They represent a cell-free approach to regenerative aesthetics.
• Preclinical research is promising. In vitro and animal studies demonstrate that MSC-derived exosomes stimulate collagen and elastin production, accelerate wound healing, promote angiogenesis, and improve skin quality markers.
• Human clinical evidence is limited. Published human data consists of small case series and pilot studies. No large randomized controlled trials have been completed for aesthetic exosome indications. The contribution of exosomes versus the delivery procedure (microneedling, laser) has not been isolated in controlled studies.
• No exosome product is FDA-approved for any aesthetic, cosmetic, or dermatologic use. The FDA has issued warnings to clinics and manufacturers, and enforcement action has occurred following adverse events.
• Product standardization does not exist. Exosome source, isolation method, concentration, cargo composition, and quality vary widely between manufacturers. The term "exosome" is used loosely in the market.
• Side effects are primarily procedure-related (redness, swelling, bruising from microneedling or laser). Exosome-specific risks include contamination in unregulated products and theoretical concerns about long-term effects.
• Cost ranges from $500–$2,500 per session, with 3–6 sessions typically recommended. Full treatment courses range from $1,500–$15,000. Insurance does not cover these treatments.
• The treatment is typically combined with microneedling or laser to breach the skin barrier and allow exosome penetration to the dermis.

Questions to Ask a Provider

• What exosome product do you use, and what is its source (cell type, manufacturer)?
• What quality testing has been performed on this product (particle count, sterility, endotoxin testing)?
• How many sessions do you recommend for my specific concerns, and what is the total expected cost?
• What results can I realistically expect, and what is the evidence supporting those expectations?
• How does this compare to other treatments (microneedling alone, PRP, laser) for my specific goals?
• What is the regulatory status of the product you use?
• What are the risks, and how do you manage potential adverse events?
• How long have you been performing exosome treatments, and how many have you done?

Sources & Further Reading

Skin Rejuvenation and Anti-Aging

• Cho BS, Kim JO, Ha DH, Yi YW (2018) — "Exosomes derived from human adipose tissue-derived mesenchymal stem cells alleviate atopic dermatitis" — Stem Cell Research & Therapy
• Kim YJ, Yoo SM, Park HH, et al. (2020) — "Exosomes derived from human umbilical cord blood mesenchymal stem cells stimulate rejuvenation of human skin" — Biochemical and Biophysical Research Communications

Wound Healing

• Hu L, Wang J, Zhou X, et al. (2019) — "Exosomes derived from human adipose mesenchymal stem cells accelerate cutaneous wound healing via optimizing the characteristics of fibroblasts" — Scientific Reports

Exosome Biology and Mechanisms

• Tkach M, Théry C (2016) — "Communication by extracellular vesicles: Where we are and where we need to go" — Cell
• Pegtel DM, Gould SJ (2019) — "Exosomes" — Annual Review of Biochemistry

Collagen and Extracellular Matrix

• Cho et al. (2018) — Collagen and elastin upregulation by ADSC exosomes
• Hu et al. (2019) — ECM remodeling in wound healing models

MicroRNA in Skin Biology

• Hu et al. (2019) — miR-21 and fibroblast function
• Kim et al. (2020) — miRNA cargo in umbilical cord MSC exosomes

Safety and Regulatory

• FDA: Important Patient and Consumer Information About Regenerative Medicine Therapies
• FDA: Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.